期刊文献+

部分常见单克隆抗体药物在抗肿瘤治疗中的应用及研究进展

Application and research progress of partial monoclonal antibody drugs in antitumor therapy
原文传递
导出
摘要 恶性肿瘤一直是发病率及死亡率均较高且严重威胁人类健康的疾病。随着医疗技术水平的提高及科学研究的深入,肿瘤的治疗除了传统的手术治疗、放射治疗和化学治疗外,免疫治疗尤其是应用单克隆抗体治疗肿瘤因其显著的治疗效果已经引起广泛关注。单克隆抗体因其靶向的抗原不同,作用机制、治疗效果及副作用等都存在差异。本文主要依据靶向抗原的不同如免疫相关抗原、肿瘤细胞表面抗原及细胞因子等就单克隆抗体在肿瘤免疫治疗中的应用进展进行综述。 Malignant tumor has always been a disease with high morbidity and mortality and a serious threat to human health.With the improvement of medical technology and the deepening of scientific research,in addition to traditional surgical treatment and radiotherapy and chemotherapy,immunotherapy,especially the application of monoclonal antibodies in the treatment of tumors,has attracted wide attention due to its remarkable therapeutic effect.There are differences in the signaling pathway,mechanism of action,therapeutic effect and side effects of monoclonal antibodies due to their different targeted antigens.In this paper,the application progress of monoclonal antibodies against the antigens such as immune-related antigens,tumor cell surface antigens and cytokines in tumor immunotherapy is reviewed based on the difference of targeted antigens.
作者 王金悦 吕桂香 高旭 WANG Jinyue;LYU Guixiang;GAO Xu(Department of Biochemistry and Molecular Biology,Harbin Medical University,Harbin 150081,China)
出处 《生命的化学》 CAS 2022年第5期950-960,共11页 Chemistry of Life
基金 哈尔滨医科大学少帅揭榜项目(HMUMIF-21025)。
关键词 免疫治疗 肿瘤 单克隆抗体 抗原 immunotherapy tumor monoclonal antibodies antigen
  • 相关文献

参考文献19

二级参考文献158

  • 1杨乔,雷建卫.曲妥珠单抗联合SOX方案在HER2阳性局部进展期胃癌新辅助治疗中的疗效[J].中国中西医结合消化杂志,2020,28(2):152-157. 被引量:9
  • 2杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1568
  • 3Kurella VB,Gali R.Structure guided homology model based design and engineering of mouse antibodies for humanization[J].Bioinformation,2014,10(4):180-186. 被引量:1
  • 4Parrena PWHI,Lugovskoy AA.Therapeutic antibody engineering[J].MAbs,2013,5(2):175-177. 被引量:1
  • 5Duvall M,Bradley N,Fiorini RN.A novel platform to produce human monoclonal antibodies:the next generation of therapeutic human monoclonal antibodies discovery[J].MAbs,2011,3(2):203-208. 被引量:1
  • 6Dantas-Barbosa C,de Macedo Brigido M,Maranhao AQ.Antibody phage display libraries:contributions to oncology[J].Int J Mol Sci,2012,13(5):5420-5440. 被引量:1
  • 7Hoffman LM,Gore L.Blinatumomab,a bi-specific anti-CD19/CD3 Bi TE?antibody for the treatment of acute lymphoblastic leukemia:perspectives and current pediatric applications[J].Front Oncol,2014,4:63. 被引量:1
  • 8Gleason MK,Ross JA,Warlick ED,Lund TC,Verneris MR,Wiernik A,et al.CD16x CD33 Bispecific killer cell engager(Bi KE)activates NK cells against primary MDS and MDSC CD33+targets[J].Blood,2014,123(19):3016-3026. 被引量:1
  • 9Han EQ,Li XL,Wang CR,Li TF,Han SY.Chimeric antigen receptor-engineered T cells for cancer immunotherapy:progress and challenges[J].J Hematol Oncol,2013,6:47. 被引量:1
  • 10Shi H,Sun M,Liu L,Wang Z.Chimeric antigen receptor for adoptive immunotherapy of cancer:latest research and future prospects[J].Mol Cancer,2014,13:219. 被引量:1

共引文献118

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部